Diabetic foot ulcers (DFUs) remain one of the most challenging complications of diabetes mellitus, with a lifetime incidence approaching 19–34% in people with diabetes and a substantial proportion progressing to infection or lower-extremity amputation. Despite advances in offloading, debridement, and infection control, roughly one-third of DFUs fail to heal within 12 weeks of best standard of care. Bioengineered skin substitutes—living cellular constructs and acellular extracellular matrix scaffolds designed to support re-epithelialization—have emerged over the past decade as adjunctive therapies for these recalcitrant wounds. This post reviews what the peer-reviewed literature from 2015–2025 reveals about their mechanisms, efficacy, and place in modern wound care.
What Are Bioengineered Skin Substitutes?
Bioengineered skin substitutes are broadly classified as cellular (containing living human keratinocytes and/or fibroblasts seeded onto a scaffold) or acellular (decellularized dermal or amniotic matrices that provide a structural and biochemical template for host tissue ingrowth). Commonly studied products include the bilayered living cellular construct Apligraf, the cryopreserved fibroblast-seeded mesh Dermagraft, the porcine small-intestinal submucosa Oasis, the human reticular acellular dermal matrix (HR-ADM), and various placental and amniotic membrane allografts.
According to the tissue-engineering review by Vijayavenkataraman and colleagues (2023), these constructs work by delivering growth factors, cytokines, and an organized extracellular matrix that recapitulate the wound microenvironment—effectively bridging the biological deficit that characterizes the chronic diabetic wound bed.
Efficacy: What Randomized Trials and Meta-Analyses Show
Cellular Constructs
A 2019 systematic review and meta-analysis by Santema et al. published in Wound Repair and Regeneration pooled data from multiple randomized controlled trials and concluded that biologic skin substitutes were significantly more effective than standard care dressings at achieving complete wound closure by 12 weeks, with relative risk improvements consistently favoring the intervention groups.
More recently, the Dermagraft and Oasis Longitudinal Comparative Efficacy Study (DOLCE), published in Diabetes Care in 2025 by Lavery and colleagues, randomized 117 patients to standard of care, a cellular matrix (Dermagraft), or an acellular matrix (Oasis) for 12 weeks. Complete re-epithelialization occurred in 49% of the cellular group, 69% of the acellular group, and 57% of the standard-of-care group—a result that did not reach statistical significance between arms but that provoked re-evaluation of assumptions about cellular superiority.
Acellular Matrices
A multicentre randomized controlled trial published in the International Wound Journal (Zelen et al., 2016) compared acellular reticular allogenic human dermis (HR-ADM) to standard of care. By six weeks, 65% of HR-ADM-treated wounds had healed compared with 5% in the standard-of-care arm; by 12 weeks the figures were 80% and 20%, respectively. A separate trial of composite split-thickness grafting with acellular dermal matrix (Hu et al., 2016) reported significantly lower 12-month recurrence (4.3% vs 22.7%) compared with conventional grafting.
Pooled Evidence
A 2025 meta-analysis published in the Journal of Vascular Surgery—Vascular Insights aggregated 29 randomized controlled trials encompassing 2,255 patients. Cellular and acellular tissue-based products combined with standard of care produced a pooled odds ratio of 2.9 for complete healing compared with standard of care alone, an effect that persisted across subgroups stratified by patient age and initial wound size.
Where Skin Substitutes Sit in Current Guidelines
The 2023 update of the IWGDF guidelines on interventions to enhance healing of foot ulcers (Chen et al., Diabetes/Metabolism Research and Reviews, 2024) reviewed nine intervention categories and issued 29 recommendations. Skin substitutes—particularly placental-derived products and the autologous leucocyte/platelet/fibrin patch—received conditional supportive recommendations for use in DFUs that have failed to progress with best standard of care alone, and only when local resources permit appropriate application and follow-up. The guidelines emphasize that these adjuncts complement, but do not replace, the foundations of wound care: offloading, vascular optimization, infection control, and sharp debridement.
Practical and Safety Considerations
The 2024 scoping review by Gushiken et al. published in the Journal of Clinical Medicine (PMC10932123) noted that overall failure rates of bioengineered products are low and that wound recurrence after closure with these technologies is comparable to, or better than, standard grafting. However, the same review highlighted heterogeneity in study design, outcome definitions, and product types as ongoing barriers to head-to-head comparison. Cost, availability, refrigeration or cryopreservation requirements, and the need for repeat applications remain important real-world considerations. Patient selection—adequate perfusion, controlled infection, and effective offloading—remains the single strongest determinant of any skin-substitute therapy’s success.
Conclusion
The accumulated evidence from 2015–2025 supports bioengineered skin substitutes as effective adjuncts to standard wound care for diabetic foot ulcers that have not responded to conventional management. Cellular and acellular products both meaningfully improve 12-week healing rates compared with standard care alone, with newer comparative trials suggesting acellular matrices may match or exceed the performance of more expensive cellular constructs. International guidelines support their conditional use, and they appear to reduce recurrence when integrated into a comprehensive limb-preservation strategy. Further high-quality head-to-head trials and standardized outcome reporting are still needed to refine product selection for individual patients.
References
- Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.
- Lavery LA, Fulmer J, Shebetka KA, et al. Cellular Versus Acellular Matrix Products for Diabetic Foot Ulcer Treatment: The Dermagraft and Oasis Longitudinal Comparative Efficacy Study (DOLCE)—A Randomized Clinical Trial. Diabetes Care. 2025;48(6):966–974.
- Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews. 2016;(2):CD011255. (See also Santema et al., systematic review on biologic skin substitutes, 2019.)
- Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. International Wound Journal. 2017;14(2):307–315.
- Hu Z, Zhu J, Cao X, et al. Composite Skin Grafting with Human Acellular Dermal Matrix Scaffold for Treatment of Diabetic Foot Ulcers: A Randomized Controlled Trial. Journal of the American College of Surgeons. 2016;222(6):1171–1179.
- Gushiken LFS, Beserra FP, Bastos JK, et al. Bioengineered Skin for Diabetic Foot Ulcers: A Scoping Review. Journal of Clinical Medicine. 2024;13(5):1221.
- Vijayavenkataraman S, et al. Tissue Engineering-Based Strategies for Diabetic Foot Ulcer Management. Cells. 2023;12(2):267.
- Meta-analysis of cellular and acellular tissue-based products demonstrates improvement of diabetic foot ulcer healing despite age and wound size. Journal of Vascular Surgery—Vascular Insights. 2025.
Comments
